January 2025 in “International Journal of Molecular Sciences” Psoriasis involves immune and genetic factors, and understanding these can improve treatments.
October 2024 in “Stem Cell Research & Therapy” CGF therapy may effectively treat psoriasis by reducing inflammation.
September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
December 2023 in “Journal of ethnopharmacology” Tribuloside can increase skin pigmentation by enhancing melanin production and distribution.
July 2022 in “Revista Ibero-Americana de Humanidades, Ciências e Educação” Many recovered COVID-19 patients, especially women, experience lingering symptoms like fatigue and headaches.
19 citations
,
July 2018 in “Medicines” Juniperus plants contain compounds with potential for developing various medical treatments.
23 citations
,
August 2018 in “Biochimica and biophysica acta. Molecular and cell biology of lipids” Different sPLA2 enzymes affect immunity, skin and hair health, reproduction, and may be potential targets for therapy.
14 citations
,
April 2021 in “Biology” Thai rice bran extracts, especially from Tubtim Chumphae rice, can significantly reduce the activity of hair loss genes, with x-tocopherol showing potential as an anti-hair loss product.
14 citations
,
April 2021 in “Frontiers in Psychiatry” Overall alcohol consumption decreased during lockdown, but heavy drinkers consumed more.
10 citations
,
May 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Hispanics in Northern Nevada had more COVID-19 cases but lower mortality than non-Hispanics.
9 citations
,
March 2022 in “Terapevticheskii arkhiv” Human placenta hydrolysates help treat various diseases and aid healing.
8 citations
,
September 2021 in “bioRxiv (Cold Spring Harbor Laboratory)” Women, younger age, and low BMI increase the risk of long COVID symptoms.
3 citations
,
July 2025 in “BIOMED natural and applied science” Drug repurposing can create safer, cheaper treatments by finding new uses for existing drugs.
3 citations
,
September 2022 in “Frontiers in psychiatry” University students in Egypt experienced high stress during COVID-19's third wave, with negative coping mechanisms being more common.
2 citations
,
September 2023 in “Curēus” Topical spironolactone may help treat ocular graft-versus-host disease with minimal side effects.
1 citations
,
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective and safe for long-term treatment of alopecia areata.
1 citations
,
June 2020 in “Dermatologic Therapy” COVID-19 can cause various skin issues, including rashes and 'COVID toes', and may worsen autoimmune diseases or affect men with baldness more severely.
January 2026 in “Revista Eletrônica Acervo Saúde” Long COVID can cause anemia and iron issues, leading to fatigue and slow recovery, especially in men and severe cases.
December 2025 in “Cureus” Post-COVID syndrome symptoms are common and overlap with general health issues.
August 2025 in “Research Square (Research Square)” High TNF-α levels may increase hair loss risk after PRP therapy.
June 2025 in “Asia-Pacific Journal of Molecular Biology and Biotechnology” Papain from papaya may help treat cardiovascular diseases by breaking down fibrin.
March 2024 in “medRxiv (Cold Spring Harbor Laboratory)” Recent selection on immune response genes was identified across seven ethnicities.
February 2024 in “Research Square (Research Square)” Proteins from Tianshan red deer abomasum have strong anti-inflammatory, anti-tumor, and antioxidant effects.
Dutasteride is more effective and better tolerated than finasteride for hair loss treatment.
January 2024 in “Fitoterapia” Vitamin D3 is crucial for immune and bone health, with most consumers being women who follow doctor advice.
December 2023 in “Y Dược học” Older adults in Vietnam often experience hair loss after COVID-19, especially women, singles, and those hospitalized.
COVID-19 may trigger or worsen rapid hair loss in alopecia areata.
January 2023 in “Book of Abstracts” The study investigated hair loss in 25 patients following COVID-19 infection, identifying various types of alopecia, with telogen effluvium (TE) being the most common. Five patients experienced acute TE, with hair loss starting a median of 2 months post-infection and lasting a median of 4 months. Fifteen patients had chronic TE, beginning a median of 6 months post-infection and lasting a median of 9 months. Additionally, five patients developed patchy alopecia areata (AA) 2-3 weeks after infection, with hair loss lasting a median of 10 months. The study highlighted that post-COVID hair loss could manifest in different alopecia types, with TE being the most prevalent.
Social media data can help track and predict COVID-19 symptoms and trends.
November 2022 in “Journal of Pharmaceutical Negative Results” Vaccination is crucial for managing Covid-19 despite new virus strains.